Mostrar el registro sencillo del ítem

Artículo

dc.creatorHajji, Nabiles
dc.creatorGarcía-Domínguez, Daniel J.es
dc.creatorHontecillas Prieto, Lourdeses
dc.creatorO'Neill, Kevines
dc.creatorÁlava Casado, Enrique dees
dc.creatorSyed, Neloferes
dc.date.accessioned2022-11-07T08:54:52Z
dc.date.available2022-11-07T08:54:52Z
dc.date.issued2021
dc.identifier.citationHajji, N., García-Domínguez, D.J., Hontecillas-Prieto, L., O'Neill, K., Álava Casado, E.d. y Syed, N. (2021). The bitter side of epigenetics: variability and resistance to chemotherapy. Epigenomics, 13 (5), 397-403. https://doi.org/10.2217/epi-2017-0112.
dc.identifier.issn1750-1911es
dc.identifier.issn1750-192X(electrónico)es
dc.identifier.urihttps://hdl.handle.net/11441/139035
dc.description.abstractOne of the major obstacles to the development of effective new cancer treatments and the main factor for the increasing number of clinical trial failures appears to be the paucity of accurate, reproducible and robust drug resistance testing methods. Most research assessing the resistance of cancers to chemotherapy has concentrated on genetic-based molecular mechanisms, while the role of epigenetics in drug resistance has been generally overlooked. This is rather surprising given that an increasing body of evidence pointing to the fact that epigenetic mechanism alterations appear to play a pivotal role in cancer initiation, progression and development of chemoresistance. This resulted in a series of clinical trials involving epi-drug as single treatment or combined with cancer conventional drugs. In this review, we provided the main mechanisms by which the epigenetic regulators control the resistance to cancer drugs.es
dc.formatapplication/pdfes
dc.format.extent7 p.es
dc.language.isoenges
dc.publisherFuture Medicinees
dc.relation.ispartofEpigenomics, 13 (5), 397-403.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCancer epigeneticses
dc.subjectEpigenetic regulationses
dc.subjectEpigenetic therapieses
dc.titleThe bitter side of epigenetics: variability and resistance to chemotherapyes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Citología e Histología Normal y Patológicaes
dc.relation.publisherversionhttps://www.scopus.com/record/display.uri?eid=2-s2.0-85102485419&origin=resultslistes
dc.identifier.doi10.2217/epi-2017-0112es
dc.journaltitleEpigenomicses
dc.publication.volumen13es
dc.publication.issue5es
dc.publication.initialPage397es
dc.publication.endPage403es

FicherosTamañoFormatoVerDescripción
The bitter side of epigenetics, ...682.2KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional